Tenax Therapeutics Approaching Crucial Study Data: Experts See High Potential in the Cardiopulmonary Portfolio

Tenax Therapeutics (TENX) is a biopharmaceutical company in clinical phase 3, focused on the identification and development of drugs for cardiovascular and pulmonary diseases with unmet medical needs. The business model is based on the further development of drug candidates that have already provided data for other indications or have novel mechanisms of action, with the goal of leading them to market approval. The centerpiece of the current pipeline is TNX-103, an oral formulation of Levosimendan. Levosimendan is a potassium channel activator...